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OBJECTIVES We sought to investigate the effects of intensive cholesterol reduction on large artery stiffness
and blood pressure in normolipidemic patients with isolated systolic hypertension (ISH).
BACKGROUND Isolated systolic hypertension is associated with elevated cardiovascular morbidity and
mortality and is primarily due to large artery stiffening, which has been independently related
to cardiovascular mortality. Cholesterol-lowering therapy has been efficacious in reducing
arterial stiffness in patients with hypercholesterolemia, and thus may be beneficial in ISH.
METHODS In a randomized, double-blinded, cross-over study design, 22 patients with stage I ISH
received three months of atorvastatin therapy (80 mg/day) and three months of placebo
treatment. Systemic arterial compliance was measured noninvasively using carotid applana-
tion tonometry and Doppler velocimetry of the ascending aorta.
RESULTS Atorvastatin treatment reduced total and low-density lipoprotein cholesterol and triglyceride
levels by 36  2% (p  0.001), 48  3% (p  0.001) and 23  5% (p  0.003), respectively,
and increased high density lipoprotein cholesterol by 7  3% (p  0.03). Systemic arterial
compliance was higher after treatment (placebo vs. atorvastatin: 0.36  0.03 vs. 0.43  0.05
ml/mm Hg, p  0.03). Brachial systolic blood pressure was lower after atorvastatin treatment
(154  3 vs. 148  2 mm Hg, p  0.03), as were mean (111  2 vs. 107  2 mm Hg, p 
0.04) and diastolic blood pressures (83  1 vs. 81  2 mm Hg, p  0.04). There was a trend
toward a reduction in pulse pressure (71  3 vs. 67  2 mm Hg, p  0.08).
CONCLUSIONS Intensive cholesterol reduction may be beneficial in the treatment of patients with ISH and
normal lipid levels, through a reduction in large artery stiffness. (J Am Coll Cardiol 2002;
39:1020–5) © 2002 by the American College of Cardiology Foundation
Isolated systolic hypertension (ISH) affects 26% of the
population 55 years (1), is associated with coronary and
cerebrovascular events (2–5) and arises as a result of large
artery stiffening (6–8). Although antihypertensive drug
therapy reduces the occurrence of fatal and nonfatal events
(9), large reductions in diastolic blood pressure (DBP) may
potentially contribute to myocardial ischemia (10). Further-
more, although antihypertensive drugs may reduce arterial
stiffness through a passive effect, few have a proven effect on
the arterial structure (11).
Cholesterol lowering is an alternative therapy that may
potentially target arterial stiffness, and thus blood pressure,
through effects on endothelial function and arterial wall
composition. A number of studies in hypercholesterolemic
patients have shown improvement, particularly in peripheral
artery properties, with cholesterol-lowering therapy (12–
16). It is unknown whether a cholesterol reduction within
the normal clinical range in patients with ISH might also
reduce stiffness of the large arteries, and thereby systolic
blood pressure (SBP). In a randomized, cross-over design,
the current study sought to examine the effects of three
months of intensive cholesterol reduction with atorvastatin
(80 mg/day) on large artery stiffness and blood pressure in
patients with stage I ISH.
METHODS
All participants gave informed consent to participate in the
study, which was undertaken with the approval of the Alfred
Healthcare Group Ethics Committee and carried out in
accordance with the Declaration of Helsinki (1989) of the
World Medical Association.
Subjects. Twenty-two patients with stage I ISH (18 men
and 4 women; mean age  SD; 60  14 years) were
recruited. Inclusion criteria for stage I ISH were a clinic
SBP 140 mm Hg, but 170 mm Hg, and DBP 90 mm
Hg. Exclusion criteria were age 80 and 18 years, low
density lipoprotein (LDL) cholesterol 2.5 mmol/l, anti-
hypertensive therapy, use of vasoactive or cholesterol-
lowering medication, excess alcohol consumption (4 stan-
dard drinks/day), smoking, coronary artery disease (based
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on history and examination) and other major medical
illness. None of the female participants were taking hor-
mone replacement therapy.
Study design. At baseline, all patients had measurements
of rest (supine) blood pressure, systemic arterial compliance
(SAC), fasting lipid profile and cardiac structure and func-
tion (by echocardiography). In a double-blinded, random-
ized, cross-over study design, patients received three months
of treatment with placebo and three months of therapy with
atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A re-
ductase inhibitor (statin), at a dose of 80 mg/day. All
measurements, except for echocardiographic ones, were
repeated in the morning after an overnight fast at three and
six months.
Cardiac structure and function. Indexes of cardiac struc-
ture and function were assessed at baseline only. Left
ventricular end-diastolic posterior wall thickness, interven-
tricular septal wall thickness at end diastole, left ventricular
internal end-diastolic diameter (LVIDD) and left ventric-
ular internal end-systolic diameter (LVIDS) were measured
using the American Society of Echocardiography conven-
tion from M-mode images of the left ventricle, generated in
the short-axis view at the level of the mitral chordae. Using
these measurements, left ventricular mass (LVM), normal-
ized for body surface area (LVM index), was estimated (17).
Left ventricular systolic function was assessed as fractional
shortening (FS), where
FS  100  LVIDD  LVIDS / LVIDD
Rest blood pressure and heart rate. Three brachial artery
blood pressure measurements and three heart rate measure-
ments were made at 3-min intervals with the use of a
Dinamap vital signs monitor (1846 SX Critikon, Tampa,
Florida), with the subjects remaining in the supine position
in a darkened, quiet room. The mean of these three values
was taken to represent the rest level.
Systemic arterial compliance. This was determined using
the method of Liu et al. (18) and validated in our laboratory
by Cameron and Dart (19). This method requires measure-
ment of carotid artery pressure by applanation tonometry,
using a Millar Mikro-Tip pressure transducer (SPT-301,
Millar Instruments, Houston, Texas), and volumetric aortic
flow (cardiac output), using a hand-held, continuous wave
Doppler velocimeter with a 3.5-MHz transducer (Multi-
Dopplex MD1, Huntleigh Technology, Cardiff, United
Kingdom), as well as two-dimensional echocardiography for
assessment of the left ventricular outflow tract area. Brachial
artery pressure was obtained simultaneously with a Di-
namap monitor and used to calibrate the carotid artery
pressure contour using diastolic and mean pressures (19).
Biochemical analyses. A 30-ml blood sample was taken at
baseline and after each intervention for enzymatic analysis
of plasma total, LDL and high-density lipoprotein (HDL)
cholesterol, triglycerides and glucose, using a Cobas-Fara
centrifugal analyzer (Roche Diagnostic Systems, Basel,
Switzerland).
Statistics. All data are presented as the mean value 
SEM, unless otherwise stated. All variables were compared
using two-way analysis of variance for repeated measures
to examine the effects of treatment (ptreatment) and order
of intervention (porder) and treatment– order interaction
(pinteraction). All statistical analyses were performed using
SPSS, version 10.0 (SPSS Inc., Chicago, Illinois).
RESULTS
The average age and body mass index of the participants
were 60  3 years and 28  1 kg/m2, respectively (height
174  2 cm; weight 83  2 kg). Indexes of cardiac structure
and function, including left ventricular mass (182  9 g),
left ventricular mass index (93  4 g/m2) and fractional
shortening (38  1%), were all within normal ranges.
Plasma glucose levels did not change with treatment (Table
1). After treatment with atorvastatin, plasma total and LDL
cholesterol and triglyceride levels were reduced, whereas
HDL cholesterol was increased, as compared with placebo
(Table 1). In addition to being reduced by atorvastatin
treatment, triglyceride levels were also significantly reduced
Abbreviations and Acronyms
ALT  alanine aminotransferase
AST  aspartate aminotransferase
DBP  diastolic blood pressure
HDL  high density lipoprotein
ISH  isolated systolic hypertension
LDL  low density lipoprotein
LVIDD  left ventricular internal end-diastolic diameter
LVIDS  left ventricular internal end-systolic diameter
MAP  mean arterial pressure
SAC  systemic arterial compliance
SBP  systolic blood pressure
TPR  total peripheral resistance
Table 1. Effects of Atorvastatin Therapy on Lipids and Glucose
Variable After Placebo After Atorvastatin ptreatment porder pinteraction
Total cholesterol (mmol/l) 5.46  0.21 3.46  0.12 0.001 0.91 0.05
LDL cholesterol (mmol/l) 3.40  0.16 1.77  0.10 0.001 0.96 0.12
HDL cholesterol (mmol/l) 1.13  0.06 1.21  0.06 0.03 0.31 0.47
Triglycerides (mmol/l) 1.38  0.13 1.00  0.08 0.003 0.002 0.68
Glucose (mmol/l) 5.65  0.30 5.28  0.17 0.11 0.52 0.25
Data are presented as the mean value  SEM. P values are presented for the effects of treatment (ptreatment), order (porder) and the interaction between treatment and order
(pinteraction).
LDL  low-density lipoprotein; HDL  high-density lipoprotein.
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with time (porder  0.002) (Table 1). Cholesterol reduction
was greater in those who received atorvastatin second
(pinteraction  0.05) (Table 1). There was no effect of the
order of intervention, nor any treatment–order interaction,
for any other variable.
Systemic arterial compliance and hemodynamic data.
After atorvastatin treatment, SAC was increased by 24 
9% (ptreatment  0.03, porder  0.48, pinteraction  0.98) (Fig.
1). Rest SBP of the brachial artery was reduced by 6 
2 mm Hg (ptreatment  0.03, porder  0.62, pinteraction 
0.76) after atorvastatin treatment, while DBP and mean
arterial pressure (MAP) were reduced by 2  1 mm Hg
(ptreatment  0.04, porder  0.19, pinteraction  0.42) and 4 
2 mm Hg (ptreatment  0.04, porder  0.79, pinteraction 
0.99), respectively (Fig. 2). There was a trend toward
reduced pulse pressure (placebo vs. atorvastatin: 71  3 vs.
67  2 mm Hg; ptreatment  0.08, porder  0.20, pinteraction 
0.44). The rest heart rate was not different between placebo
and atorvastatin treatment (64  2 vs. 64  2 beats/min;
ptreatment  0.83, porder  0.45, pinteraction  0.12). Total
peripheral resistance (TPR) was reduced after atorvastatin
treatment (22.8  1.8 vs. 18.9  1.4 U; ptreatment  0.05,
porder  0.15, pinteraction  0.73), although there was no
change in cardiac output (ptreatment  0.12, porder  0.67,
pinteraction  0.57). In addition, blood pressure and heart
rate were not different when taken during measurement of
SAC (data not shown).
Safety variables. At baseline, three patients had plasma
alanine aminotransferase (ALT) levels above the normal
upper limit of 40 U/l, but all patients had aspartate
aminotransferase (AST) levels below the normal upper limit
of 50 U/l. After atorvastatin treatment, versus placebo, there
was a significant rise in both ALT (27  3 vs. 42  6 U/l;
ptreatment  0.05, porder  0.53, pinteraction  0.35) and AST
(24  1 vs. 30  3 U/l; ptreatment  0.05, porder  0.08,
pinteraction  0.30). Treatment increased ALT levels above
40 U/l in seven patients and AST levels above 50 U/l in two
patients, but no patient was beyond three times the normal
range. No patient complained of myalgia.
DISCUSSION
Intensive cholesterol reduction with atorvastatin (80 mg/
day) over three months reduced large artery stiffness and
blood pressure in normocholesterolemic patients with stage
I ISH. Total and LDL cholesterol and triglyceride levels
were reduced to a similar extent, as reported in hypercho-
lesterolemic patients (20,21), and HDL cholesterol was
significantly increased by treatment. As ISH is a condition
characterized by the presence of stiffened arteries (6–8),
cholesterol-lowering therapy may slow progression. Fur-
thermore, a reduction of large artery stiffness may contribute
to the long-term benefits of statins, with regard to the risk
of coronary events and stroke (22).
Blood pressure reduction has not previously been re-
ported with intensive cholesterol reduction in normolipi-
demic patients. Furthermore, blood pressure reduction does
not occur with statin treatment in hypercholesterolemic,
normotensive patients (13,16,23–25). In patients with con-
trolled hypertension who were also hypercholesterolemic,
two studies found no change in blood pressure levels with
additional statin treatment (26,27), whereas others demon-
strated that additional statin therapy led to a greater
reduction in SBP, MAP and DBP (28,29). Collectively, this
suggests that statins may be more effective in lowering
elevated, but not normal, blood pressure levels, regardless of
cholesterol levels.
In the current study, a reduction in large artery stiffness
probably underlies the reduced SBP and trend for reduced
pulse pressure, however MAP fell slightly due to a reduction
Figure 1. Systemic arterial compliance (SAC) after placebo administration
(open bar) and after atorvastatin treatment (solid bar). *ptreatment  0.03,
porder  0.48, pinteraction  0.98). Data are presented as the mean value 
SEM.
Figure 2. Rest blood pressure of the brachial artery after placebo admin-
istration and after atorvastatin treatment. The top portion of each bar
represents systolic blood pressure (SBP); the white band in the middle
represents mean arterial pressure (MAP); and the base portion of each bar
represents diastolic blood pressure (DBP). Each pressure variable was
analyzed in a separate two-way repeated measures analysis of variance and
was significantly lower after atorvastatin treatment (*ptreatment 0.05 for
SBP, DBP and MAP; both porder and pinteraction were 0.05 for all
variables; see text for individual p values). Data are presented as the mean
value  SEM.
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in TPR. As arterial stiffness is dependent on MAP (18), any
reduction in MAP leads to a passive decrease in arterial
stiffness, and thus may partly account for the observed
arterial compliance changes. However, the reduction in
MAP was small, and it is likely that the passive reduction in
stiffness was also minimal, implying that atorvastatin also
had direct effects on the arterial wall.
Previous studies have found that cholesterol-lowering
therapy reduces arterial stiffness in the descending aorta (14)
and carotid (13), femoral (12,13) and brachial (16) arteries
of patients with familial hypercholesterolemia. Interestingly,
only studies in which cholesterol-lowering therapy was
taken for 12 months reported a reduction in arterial
stiffness (13,14,16,23), as compared with a shorter six-
month intervention study examining brachial artery stiffness
(25). In nonfamilial hypercholesterolemic patients, four
weeks of cholesterol-lowering therapy failed to alter central
or descending aortic stiffness, although it did reduce stiffness
from the femoral artery to the foot (15), whereas eight
weeks of statin therapy had no effect on carotid, femoral or
brachial artery stiffness in another study (24). The shorter
period in which alterations were observed in the current
study may be due to the different patient group, which,
besides having higher blood pressure and stiff large arteries,
had relatively normal cholesterol levels. Atorvastatin was
also used at a maximal dose in the current study, and at this
dose, it has greater efficacy for LDL reduction, as compared
with pravastatin or simvastatin (20), which were used in
some of the shorter trials (15,24,25).
Mechanisms. Large artery stiffening in patients with ISH
may relate to alterations in the extracellular matrix, changes
in smooth muscle content, endothelial injury and athero-
sclerotic lesion formation. Favorable alterations in any of
these variables could bring about improvements in arterial
stiffness.
The rapid time frame for the observed pressure and
arterial compliance changes is compatible with changes in
endothelial function, which is improved with cholesterol-
lowering therapy in patients with hypercholesterolemia (30),
hypertriglyceridemia (31) and coronary artery disease
(32,33) and in those who have had acute coronary syn-
dromes (34). Benefits occur quickly, with one study report-
ing improvements after four weeks of therapy (35). Statins
increase the availability of nitric oxide through an increase in
endothelial nitric oxide synthase activity and expression
(36,37) and also inhibit endothelin-1 production (38). The
consequent vasodilation that occurs with an improvement in
endothelial function may contribute to the reduction in
MAP, and hence indirectly to the increase in arterial
compliance. In addition, improved endothelial function in
both the aorta and vasa vasorum (39) may directly affect
large artery stiffness.
Atherosclerotic regression has been associated with im-
provement in arterial stiffness (40), raising the possibility
that atorvastatin may modify aortic atherosclerotic lesions.
Statin therapy for as little as eight weeks causes atheroscle-
rotic plaque modification in rabbits (41–44). A reduction in
platelet deposition and nitric oxide-mediated leukocyte
rolling, adherence and transmigration, all the result of statin
treatment, may contribute to plaque stabilization and re-
gression (45,46). A reduction in matrix metalloproteinase
expression may also contribute, because these enzymes are
secreted by atheromatous cells and have been implicated in
the weakening of the fibrous cap in unstable plaques (47).
Statin treatment reduces matrix metalloproteinase expres-
sion in human carotid plaques (48) and rabbit aortic
atheroma (49), and may therefore inhibit degradation of the
elastic matrix and decrease stiffness.
Study implications. Patients with ISH who have stiff large
arteries are at an elevated risk for stroke and coronary events.
The risk for the latter relates to both elevated cardiac
afterload (50) and promotion of left ventricular hypertrophy
(51), in addition to restricted coronary perfusion arising
from low diastolic pressure (52,53). The current data indi-
cate that in normolipidemic patients with ISH, intensive
lipid-lowering therapy for three months has efficacy in
targeting large artery stiffness, which is the underlying cause
of ISH. Such therapy may be beneficial in slowing the
progression of ISH and reducing coronary disease-
associated risk. Larger clinical trials are warranted to con-
firm these data.
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